An interventional study of MRI exam in Bipolar Disorder, sponsored by Assistance Publique Hopitaux De Marseille. Completed at 1 site in France. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies in Bipolar Disorder with a site in France — 34 open to participants now, 38 under way, 1 of them phase 3. Bipolar Disorder · France.
Among the 104 studies in Bipolar Disorder with a site in France, this one is the 46th largest by enrollment of the 79 interventional ones that give a count, is one of 7 that started in 2023, is one of 56 with no phase, and was the 80th registered.
1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →34 of the 104 studies in Bipolar Disorder with a site in France are open now. Recruiting first, the newest first:
CHU de Reims · Sites in France
Ages 18–65 · Healthy volunteers
Centre Hospitalier St Anne · Sites in France
Ages 18+
Fondation FondaMental · Sites in France
Ages 15–60 · Healthy volunteers
Hospital Center Guillaume Régnier · Sites in France
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 18–45 · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 16 · Phase 4 2
First in 2004; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is above the median of 64 across 1,282 interventional studies indexed under Bipolar Disorder.
Median enrollment 170 across the 79 interventional studies, 100 across the 25 observational. Of the 46 that completed or were terminated, 12 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 104 have an industry lead sponsor. The 10 most frequent:
Assistance Publique Hopitaux De Marseille is the lead sponsor of 702 studies on the registry; 139 are open to participants now.
Assistance Publique Hopitaux De Marseille has 6 studies filed under Bipolar Disorder — fewer than ten, so there is no comparison to draw.
10 of the studies in Bipolar Disorder with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07140913Phase 3Bristol-Myers SquibbA Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine | 2027-06-28 |
| NCT07316803Centre hospitalier de Ville-Evrard, FranceGroup Intervention for Romantic Relationships in Young Adults With Severe Mental Illness | 2026-11-30 |
| NCT04917419Centre Hospitalier Henri LaboritNursing Care of Bipolar Patients With Sleeping Disorders Using Luminotherapy and /or Psychoeducation Program (BIPLUMINO) | 2026-12 |
| NCT05878730Assistance Publique - Hôpitaux de ParisMelatonin and Response to Lithium | 2026-12 |
| NCT06059313Nantes University HospitalPremorbid Personality Profile of Patients With Cognitive and Behavioral Disorders | 2026-12-14 |
Add all 10 to your calendar (.ics) → With an account.
Among the 104 studies in Bipolar Disorder with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Given the phenotypic heterogeneity of bipolar disorder, it seems essential to propose new methodologies to improve the stratification of this pathology in order to describe more homogeneous groups of patients. In this perspective, the neurodevelopmental hypothesis of bipolar disorder seems promising. Brain sulcation is an indirect marker of neurodevelopmental processes. The objective of the study is to highlight sulcal variations between a group of bipolar patients with a neurodevelopmental phenotype (ND) and a group of bipolar subjects without a ND phenotype. A sulcation marker (GPR56) will also be measured from patient blood samples. In order to carry out this project 120 participants will be included for a period of 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For the "neurodevelopmental" group :
The volunteer has at least 2 of the 12 neurodevelopmental criteria
For the "non-neurodevelopmental" group The volunteer does not present any of the 12 neurodevelopmental criteria
List of the 12 neurodevelopmental criteria :
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The volunteer presents at least 2 of 12 neurodevelopmental crieria
Other: MRI exam
The volunteer does not present any of the 12 neurodevelopmental crieria
Other: MRI exam
Brain MRI Morphometric exam
Diifference in the occurrence of sulcal pits allowing to discriminate between a group of bipolar patients presenting a neurodevelopmental phenotype and a group of bipolar patients not presenting this phenotype.
Patients are identified in the neurodevelopmental group following a list of 12 criteria (0 criterion = non neurodevelopmental, at leat 2 criteria = neurodevelopmental)
Time frame: 24 months
The depth and number of sulcal pits to differentiate a group of bipolar patients with a neurodevelopmental phenotype from a group of bipolar patients without this phenotype.
Patients are identified in the neurodevelopmental group following a list of 12 criteria (0 criterion = non neurodevelopmental, at leat 2 criteria = neurodevelopmental)
Time frame: 24 months
The demonstration of correlations between different scores used in the clinic that may be related to neurodevelopmental manifestations of bipolar disorder (scales: WURS, minor neurological signs scale) and the number of sulcal-pits.
Patients are identified in the neurodevelopmental group following a list of 12 criteria (0 criterion = non neurodevelopmental, at leat 2 criteria = neurodevelopmental)
Time frame: 24 months
The blood level of GRP56 messenger RNA measured in whole blood by quantitative PCR to differentiate a group of bipolar patients with a neurodevelopmental phenotype and a group of bipolar patients without this phenotype
Patients are identified in the neurodevelopmental group following a list of 12 criteria (0 criterion = non neurodevelopmental, at leat 2 criteria = neurodevelopmental)
Time frame: 24 months
Genetic polymorphisms of GPR56 to differentiate between a group of bipolar patients with a neurodevelopmental phenotype and a group of bipolar patients without this phenotype
Patients are identified in the neurodevelopmental group following a list of 12 criteria (0 criterion = non neurodevelopmental, at leat 2 criteria = neurodevelopmental)
Time frame: 24 months
Protein quantification of the circulating fraction of GP56 in plasma and serum to differentiate a group of bipolar patients with a neurodevelopmental phenotype from a group of bipolar patients without this phenotype.
Patients are identified in the neurodevelopmental group following a list of 12 criteria (0 criterion = non neurodevelopmental, at leat 2 criteria = neurodevelopmental)
Time frame: 24 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2023 to primary completion in Jun 2025, 28 months.
Of 361 non-industry interventional studies with no phase under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's 28 months is below that.
Counting every sponsor, half of 363 studies reached it within 37 months; a quarter within 23 and three quarters within 58.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Jan 2025 → Jun 2025 and completion Jan 2025 → Jun 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique Hopitaux De Marseille →